# MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

> **NCT04110301** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Mabworks Biotech Co., Ltd.** · enrollment: 53 (estimated)

## Conditions studied

- Follicular Lymphoma and Marginal Zone Lymphoma

## Interventions

- **DRUG:** Recombinant Humanized Monoclonal Antibody MIL62 Injection
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT04110301
- **Lead sponsor:** Beijing Mabworks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-11-28
- **Primary completion:** 2024-01-09
- **Final completion:** 2025-05
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04110301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04110301, "MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04110301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*